Zacks Small Cap Analysis – MTVA: Compelling Information for DA-1241 in Section 2a MASH Trial… – Tech Cyber Internet
By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Enterprise Replace Compelling Outcomes for DA-1241 in Section 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) introduced constructive topline outcomes from the 16-week Section 2a scientific trial of DA-1241 in sufferers with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial had two elements: … Read more
